Jim Mazzola
Investor Relations Contact bij OUTSET MEDICAL, INC.
Actieve functies van Jim Mazzola
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
OUTSET MEDICAL, INC. | Investor Relations Contact | 01-01-2022 | - |
Loopbaan van Jim Mazzola
Eerdere bekende functies van Jim Mazzola
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
CAREFUSION CORPORATION | Investor Relations Contact | 01-09-2008 | 01-03-2015 |
Public Communications Contact | 01-09-2008 | 01-03-2015 | |
Verkoop & Marketing | 01-09-2008 | 01-03-2015 | |
CARDINAL HEALTH, INC. | Public Communications Contact | 01-09-2003 | 01-09-2008 |
CareFusion Foundation | President | - | - |
HALOZYME THERAPEUTICS, INC. | Investor Relations Contact | - | - |
Public Communications Contact | - | - | |
TURG POIN | Investor Relations Contact | - | - |
Opleiding van Jim Mazzola
University of Dayton | Masters Business Admin |
Statistieken
Internationaal
Verenigde Staten | 8 |
Operationeel
Investor Relations Contact | 4 |
Public Communications Contact | 3 |
Sales & Marketing | 1 |
Sectoraal
Health Technology | 4 |
Distribution Services | 3 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
CARDINAL HEALTH, INC. | Distribution Services |
HALOZYME THERAPEUTICS, INC. | Health Technology |
OUTSET MEDICAL, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
CareFusion Corp.
CareFusion Corp. Medical DistributorsDistribution Services CareFusion Corp. engages in the manufactures of medical equipment and device. The company was founded on February 4, 2009 and is headquartered in San Diego, CA. | Distribution Services |
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
CareFusion Foundation |
- Beurs
- Insiders
- Jim Mazzola
- Ervaring